



--- Dashed lines indicate options where the proband/substitute decision maker must indicate a preference for the analysis of secondary findings.

\* Unless preference was indicated prior to loss of competence

† The [ACMG SF v2.0](#) list is defined by: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics ([PMID 27854360](#)).